Preliminary Report of Intravenous Tolvaptan Sodium Phosphate (Samtas^®) Treatment in Decompensated Heart Failure

Keyphrases

• Academic Medical Centers 16%
• Acute Decompensated Heart Failure 100%
• Aquaretic 16%
• Clinical Data 16%
• Congestion 33%
• Congestive Heart Failure 33%
• Continuous Hemodiafiltration 16%
• Conventional Diuretics 16%
• Diuretics 16%
• Heart Failure Patients 16%
• Hospitalized Patients 16%
• Hypernatremia 16%
• Inotropes 16%
• Japan 16%
• N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) 16%
• Noninvasive Positive Pressure Ventilation 16%
• Oral Intake 33%
• Phosphate Treatment 33%
• Real-world Clinical Practice 16%
• Retrospective Analysis 16%
• Routine Clinical Practice 16%
• Sodium Phosphate 100%
• Tokyo 16%
• Tolvaptan 100%
• Unstable Hemodynamics 16%
• Urine Osmolality 16%
• Urine Volume 16%

Medicine and Dentistry

• Amiloride Plus Hydrochlorothiazide 16%
• Amino Terminal Sequence 16%
• Brain Natriuretic Peptide 16%
• Congestive Heart Failure 33%
• Continuous Hemodiafiltration 16%
• Continuous Positive Airway Pressure 16%
• Decompensated Heart Failure 100%
• Diuretic Agent 33%
• Hemodynamic 16%
• Hospital Inpatient 16%
• Hypernatremia 16%
• Inotropic Agent 16%
• Sodium Dihydrogen Phosphate 100%
• Tolvaptan 100%